Vancomycin-resistant Staphylococcus aureus pathophysiology
Vancomycin-resistant Staphylococcus aureus Microchapters |
Diagnosis |
---|
Treatment |
Case Studies |
Vancomycin-resistant Staphylococcus aureus pathophysiology On the Web |
American Roentgen Ray Society Images of Vancomycin-resistant Staphylococcus aureus pathophysiology |
FDA on Vancomycin-resistant Staphylococcus aureus pathophysiology |
CDC on Vancomycin-resistant Staphylococcus aureus pathophysiology |
Vancomycin-resistant Staphylococcus aureus pathophysiology in the news |
Blogs on Vancomycin-resistant Staphylococcus aureus pathophysiology |
Directions to Hospitals Treating Vancomycin-resistant Staphylococcus aureus |
Risk calculators and risk factors for Vancomycin-resistant Staphylococcus aureus pathophysiology |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]
Please help WikiDoc by adding more content here. It's easy! Click here to learn about editing.
Overview
VISA and VRSA are specific types of antimicrobial-resistant Staphylococcus aureus. Staphylococcus aureus, often simply referred to as “staph”, are bacteria commonly found on the skin and in the nose of healthy people. Occasionally, they can cause infection and they are one of the most common causes of skin infections in the United States.